WO2006061156A3 - Arzneimittel zur hygienischen applikation im ohr - Google Patents

Arzneimittel zur hygienischen applikation im ohr Download PDF

Info

Publication number
WO2006061156A3
WO2006061156A3 PCT/EP2005/012978 EP2005012978W WO2006061156A3 WO 2006061156 A3 WO2006061156 A3 WO 2006061156A3 EP 2005012978 W EP2005012978 W EP 2005012978W WO 2006061156 A3 WO2006061156 A3 WO 2006061156A3
Authority
WO
WIPO (PCT)
Prior art keywords
ear
medicament
application inside
hygienic application
hygienic
Prior art date
Application number
PCT/EP2005/012978
Other languages
English (en)
French (fr)
Other versions
WO2006061156A2 (de
Inventor
Iris Heep
Gert Daube
Ernst Boettcher
Dirk Mertin
Original Assignee
Bayer Healthcare Ag
Iris Heep
Gert Daube
Ernst Boettcher
Dirk Mertin
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to US11/721,204 priority Critical patent/US20090011045A1/en
Priority to CA002594103A priority patent/CA2594103A1/en
Priority to MX2007006689A priority patent/MX2007006689A/es
Priority to JP2007544787A priority patent/JP2008522998A/ja
Priority to NZ555640A priority patent/NZ555640A/en
Priority to AU2005313602A priority patent/AU2005313602A1/en
Application filed by Bayer Healthcare Ag, Iris Heep, Gert Daube, Ernst Boettcher, Dirk Mertin filed Critical Bayer Healthcare Ag
Priority to EP05816509A priority patent/EP1830803A2/de
Priority to BRPI0518855-5A priority patent/BRPI0518855A2/pt
Publication of WO2006061156A2 publication Critical patent/WO2006061156A2/de
Publication of WO2006061156A3 publication Critical patent/WO2006061156A3/de
Priority to IL183744A priority patent/IL183744A0/en
Priority to NO20073148A priority patent/NO20073148L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0046—Ear
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61D—VETERINARY INSTRUMENTS, IMPLEMENTS, TOOLS, OR METHODS
    • A61D7/00—Devices or methods for introducing solid, liquid, or gaseous remedies or other materials into or onto the bodies of animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines having two or more nitrogen atoms in the same ring, e.g. oxadiazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M31/00—Devices for introducing or retaining media, e.g. remedies, in cavities of the body

Abstract

Die Erfindung betrifft ein System zur hygienischen Applikation eines Ohrenmedikaments - insbesondere bei Tieren -, welches selbst bei geringen Volumina reproduzierbar zu dosieren ist und welches selbst bei Schütteln des Kopfes nicht wieder herausgeschleudert wird.
PCT/EP2005/012978 2004-12-09 2005-12-03 Arzneimittel zur hygienischen applikation im ohr WO2006061156A2 (de)

Priority Applications (10)

Application Number Priority Date Filing Date Title
CA002594103A CA2594103A1 (en) 2004-12-09 2005-12-03 Medicament for hygienic application inside the ear
MX2007006689A MX2007006689A (es) 2004-12-09 2005-12-03 Medicamento para administracion higienica en el oido.
JP2007544787A JP2008522998A (ja) 2004-12-09 2005-12-03 耳内部での衛生的使用のための薬剤
NZ555640A NZ555640A (en) 2004-12-09 2005-12-03 Pharmaceutical for hygienic administration in the ear containing a fluoroquinolone such as enrofloxacin, pradofloxacin or marbofloxacin and an oily liquid base
AU2005313602A AU2005313602A1 (en) 2004-12-09 2005-12-03 Medicament for hygienic application inside the ear
US11/721,204 US20090011045A1 (en) 2004-12-09 2005-12-03 Pharmaceutical for Hygienic Administration in the Ear
EP05816509A EP1830803A2 (de) 2004-12-09 2005-12-03 Arzneimittel zur hygienischen applikation im ohr
BRPI0518855-5A BRPI0518855A2 (pt) 2004-12-09 2005-12-03 medicamento para aplicaÇço higiÊnica no ouvido
IL183744A IL183744A0 (en) 2004-12-09 2007-06-07 Medicament for hygienic application inside the ear
NO20073148A NO20073148L (no) 2004-12-09 2007-06-20 Medikament for hygienisk paforing pa innsiden av oret

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DE102004059220 2004-12-09
DE102004059220.9 2004-12-09
DE102005055385A DE102005055385A1 (de) 2004-12-09 2005-11-17 Arzneimittel zur hygienischen Applikation im Ohr
DE102005055385.0 2005-11-17

Publications (2)

Publication Number Publication Date
WO2006061156A2 WO2006061156A2 (de) 2006-06-15
WO2006061156A3 true WO2006061156A3 (de) 2006-08-24

Family

ID=35735089

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2005/012978 WO2006061156A2 (de) 2004-12-09 2005-12-03 Arzneimittel zur hygienischen applikation im ohr

Country Status (19)

Country Link
US (1) US20090011045A1 (de)
EP (1) EP1830803A2 (de)
JP (1) JP2008522998A (de)
KR (1) KR20070086799A (de)
AR (1) AR052990A1 (de)
AU (1) AU2005313602A1 (de)
BR (1) BRPI0518855A2 (de)
CA (1) CA2594103A1 (de)
CR (1) CR9142A (de)
DE (1) DE102005055385A1 (de)
GT (1) GT200500361A (de)
IL (1) IL183744A0 (de)
MX (1) MX2007006689A (de)
NO (1) NO20073148L (de)
NZ (1) NZ555640A (de)
PE (1) PE20061145A1 (de)
RU (1) RU2431486C2 (de)
TW (1) TW200637611A (de)
WO (1) WO2006061156A2 (de)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101861169B (zh) * 2007-11-19 2012-09-26 拜尔动物保健有限责任公司 包含疏水性硅石的油状悬浮液的稳定化

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102006049520A1 (de) 2006-10-20 2008-04-24 Bayer Healthcare Ag Verfahren zur Herstellung von Pradofloxacin
GR20090100230A (el) 2009-04-14 2010-11-18 Casso Pharmaceuticals Ε.Π.Ε, Απο του στοματος εναιωρημα οξικης δεξαμεθανοζης-συνθεση καλυψης γευσης της δεξαμεθανοζης
PL2802209T3 (pl) * 2012-01-10 2021-07-05 Entrx LLC Preparaty do uszu
US9849126B2 (en) 2013-01-03 2017-12-26 Entrx LLC Sterile otic formulations
MD4291C1 (ro) * 2013-12-27 2015-02-28 Государственный Медицинский И Фармацевтический Университет "Nicolae Testemitanu" Республики Молдова Preparat medicamentos pentru tratamentul otitelor
SI3397651T1 (sl) 2015-12-29 2020-11-30 Galderma S.A. Oglikovodično zamreževalo
KR20190024983A (ko) * 2016-06-29 2019-03-08 오토노미, 인코포레이티드 트리글리세라이드 귀 제제 및 이의 용도
WO2018146194A1 (en) * 2017-02-13 2018-08-16 Bayer Animal Health Gmbh Liquid composition containing pradofloxacin
CA3098060A1 (en) 2018-04-25 2019-10-31 Bayer Animal Health Gmbh Process for the hydrolysis of quinolone carboxylic esters
CA3127151A1 (en) 2019-02-19 2020-08-27 Laboratorios Salvat, S.A. Single-dose packaged clotrimazole liquid composition
US11235087B2 (en) * 2019-10-28 2022-02-01 Galderma Holding SA Ready-to-use esthetic compositions
RU2758056C2 (ru) * 2019-11-21 2021-10-26 федеральное государственное бюджетное образовательное учреждение высшего образования "Ставропольский государственный аграрный университет" Препарат для лечения отитов бактериальной и грибковой этиологии у собак
CA3160575A1 (en) 2019-12-02 2021-06-10 Johan Olsson High molecular weight esthetic compositions

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS61167614A (ja) * 1985-01-22 1986-07-29 Mitsubishi Yuka Yakuhin Kk ステロイド含有軟膏剤
US4835142A (en) * 1983-08-01 1989-05-30 Teijin Limited Powdery pharmaceutical composition suitable for application to mucosa of oral or nasal cavity
EP0733357A1 (de) * 1995-03-22 1996-09-25 Dompé S.P.A. Arzneizubereitungen in Form eines thixotropen Gels
EP1228784A2 (de) * 2001-02-06 2002-08-07 Laboratorios Del Dr. Esteve, S.A. Veterinäre Zusammensetzungen
EP1384478A1 (de) * 1998-09-30 2004-01-28 Alcon, Inc Antibiotische zusammensetzung, die quinolone derivaten enthält, zur behandlung von augen, oren und nase
WO2004050021A2 (en) * 2002-11-27 2004-06-17 Regents Of The University Of Minnesota Methods and compositions for applying pharmacologic agents to the ear
WO2005077360A2 (en) * 2004-02-05 2005-08-25 Fairfield Clinical Trials, Llc Topical treatment of otitis externa with antifungals or antibacterials

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1572226A (en) * 1977-11-03 1980-07-30 Hoechst Uk Ltd Pharmaceutical preparations in solid unit dosage form
JPS5746986A (en) * 1980-09-02 1982-03-17 Dai Ichi Seiyaku Co Ltd Pyrido(1,2,3-de)(1,4)benzoxazine derivative
US4670444B1 (en) * 1980-09-03 1999-02-09 Bayer Ag and-naphthyridine-3-carboxylic acids and antibacte7-amino-1-cyclopropyl-4-oxo-1,4-dihydro-quinoline-rial agents containing these compounds
US4472405A (en) * 1982-11-12 1984-09-18 Riker Laboratories, Inc. Antimicrobial 6,7-dihydro-5,8-dimethyl-9 fluoro-1-oxo-1H, 5H-benzo (ij) quinolizine-2-carboxylic acid and derivatives
US4730000A (en) * 1984-04-09 1988-03-08 Abbott Laboratories Quinoline antibacterial compounds
DE3333719A1 (de) * 1983-09-17 1985-04-04 Bayer Ag Loesungen milchsaurer salze von piperazinylchinolon- und piperazinyl-azachinoloncarbonsaeuren
AT392789B (de) * 1985-01-23 1991-06-10 Toyama Chemical Co Ltd Verfahren zur herstellung von 1-substituierten aryl-1,4-dihydro-4-oxonaphthyridinderivaten
IN166416B (de) * 1985-09-18 1990-05-05 Pfizer
DE3537761A1 (de) * 1985-10-24 1987-04-30 Bayer Ag Infusionsloesungen der 1-cyclopropyl-6-fluor-1,4-dihydro-4-oxo-7- (1-piperazinyl)-chinolin-3-carbonsaeure
DE3713672A1 (de) * 1987-04-24 1988-11-17 Bayer Ag Verfahren zur herstellung von parenteral verabreichbaren chinoloncarbonsaeuren
US5444096A (en) * 1989-06-02 1995-08-22 Helene Curtis, Inc. Stable anhydrous topically-active composition and suspending agent therefor
US5665384A (en) * 1990-04-06 1997-09-09 Rhone-Poulenc Rorer S.A. Oily capsules of ketoprofen
DE19500784A1 (de) * 1995-01-13 1996-07-18 Bayer Ag Enrofloxacin-Injektions- oder Infusionslösungen
US5843930A (en) * 1995-06-06 1998-12-01 Bayer Corporation Method of treating otitis with ciprofloxacin-hydrocortisone suspension
CA2176298C (en) * 1995-06-27 2009-01-27 Dennis D. Copeland A single high dose fluoroquinolone treatment
US5753269A (en) * 1995-12-27 1998-05-19 Bayer Corporation Otic microbial combinations
DK0882049T3 (da) * 1996-02-23 2003-03-03 Bayer Ag Eventuelt substituerede 8-cyan-1-cyclopropyl-7-(2,8-diazabicyclo-[4.3.0]nonan-8-yl)-6-fluor-1,4-dihydro-4-oxo-3-quinolincarboxylsyrer og deres derivater
US5972920A (en) * 1998-02-12 1999-10-26 Dermalogix Partners, Inc. Formulation containing a carrier, active ingredient, and surfactant for treating skin disorders
FR2781373B1 (fr) * 1998-07-07 2001-09-21 Pf Medicament Formulations thixotropes pour le remplissage de gelules
US6440964B1 (en) * 1998-09-30 2002-08-27 Alcon Manufacturing, Ltd. Compositions and methods for treating ophthalmic and otic infections
DE19854355A1 (de) * 1998-11-25 2000-05-31 Bayer Ag Kristallmodifikation B von 8-Cyan-1-cyclopropyl-7-(1S, 6S-2,8-diazabicyclo-/4.3.O/nonan-8-yl)-6-fluor-1,4-dihydro-4-oxo-3-chinolincarbonsäure
EP1156829B1 (de) * 1999-02-26 2007-05-09 Sanofi-Aventis Stabile fumagillin-formulierung
EP1181013B1 (de) * 1999-04-14 2006-10-11 Dana-Farber Cancer Institute, Inc. Verfahren und zusammansetzung zur behandlung von krebs
JP2004509918A (ja) * 2000-09-25 2004-04-02 バイエル・ヘルスケア・エルエルシー 鼓膜の破れた動物の治療のための耳治療用の抗微生物剤の組み合わせ物
MXPA04002576A (es) * 2001-09-21 2004-06-18 Alcon Inc Metodo para tratar infecciones del oido medio.
US20040214753A1 (en) * 2003-03-20 2004-10-28 Britten Nancy Jean Dispersible pharmaceutical composition for treatment of mastitis and otic disorders
CN1901863A (zh) * 2003-11-13 2007-01-24 康宾纳特克斯公司 治疗炎性疾病的方法和药物
US7764972B2 (en) * 2004-02-17 2010-07-27 Vocera Communications, Inc. Heterogeneous device chat room system and method
AU2005272925B2 (en) * 2004-08-13 2011-02-10 Intervet International B.V. Pharmaceutical formulation comprising an antibiotic, a triazole and a corticosteroid

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4835142A (en) * 1983-08-01 1989-05-30 Teijin Limited Powdery pharmaceutical composition suitable for application to mucosa of oral or nasal cavity
JPS61167614A (ja) * 1985-01-22 1986-07-29 Mitsubishi Yuka Yakuhin Kk ステロイド含有軟膏剤
EP0733357A1 (de) * 1995-03-22 1996-09-25 Dompé S.P.A. Arzneizubereitungen in Form eines thixotropen Gels
EP1384478A1 (de) * 1998-09-30 2004-01-28 Alcon, Inc Antibiotische zusammensetzung, die quinolone derivaten enthält, zur behandlung von augen, oren und nase
EP1228784A2 (de) * 2001-02-06 2002-08-07 Laboratorios Del Dr. Esteve, S.A. Veterinäre Zusammensetzungen
WO2004050021A2 (en) * 2002-11-27 2004-06-17 Regents Of The University Of Minnesota Methods and compositions for applying pharmacologic agents to the ear
WO2005077360A2 (en) * 2004-02-05 2005-08-25 Fairfield Clinical Trials, Llc Topical treatment of otitis externa with antifungals or antibacterials

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
DATABASE CA [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; 15 October 1986 (1986-10-15), "Steroid-containing ointments", XP002367668, retrieved from STN Database accession no. 105:178480 *
FACHINFO SERVICE: "Polyspectran HC Salbe", 2003, ROTE LISTE SERVICE GMBH, BERLIN, XP002367666 *
JENSEN E ET AL: "N-Substituted (aminomethyl)benzoate 21-esters of corticosteroids as water-soluble, solution-stable and biolabile prodrugs", ACTA PHARMACEUTICA NORDICA, ELSEVIER SCIENCE PUBLISHERS, AMSTERDAM, NL, vol. 4, no. 1, 1992, pages 35 - 42, XP002249867, ISSN: 1100-1801 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101861169B (zh) * 2007-11-19 2012-09-26 拜尔动物保健有限责任公司 包含疏水性硅石的油状悬浮液的稳定化

Also Published As

Publication number Publication date
BRPI0518855A2 (pt) 2008-12-09
CR9142A (es) 2007-12-04
EP1830803A2 (de) 2007-09-12
US20090011045A1 (en) 2009-01-08
RU2007125570A (ru) 2009-01-20
TW200637611A (en) 2006-11-01
AU2005313602A1 (en) 2006-06-15
NO20073148L (no) 2007-08-22
CA2594103A1 (en) 2006-06-15
RU2431486C2 (ru) 2011-10-20
NZ555640A (en) 2009-12-24
WO2006061156A2 (de) 2006-06-15
MX2007006689A (es) 2007-08-14
DE102005055385A1 (de) 2006-06-14
AR052990A1 (es) 2007-04-18
PE20061145A1 (es) 2006-12-29
KR20070086799A (ko) 2007-08-27
IL183744A0 (en) 2008-04-13
JP2008522998A (ja) 2008-07-03
GT200500361A (es) 2006-11-07

Similar Documents

Publication Publication Date Title
WO2006061156A3 (de) Arzneimittel zur hygienischen applikation im ohr
EP1992290A4 (de) Ultraschallvibrator und körperhöhlen-ultraschallgerät mit ultraschallvibrator
EP1768546B8 (de) Medizinisches körperkern-thermometer
EP1810619A4 (de) Kapazitiver ultraschallwandler und diesen verwendendes endohohlraum-ultraschalldiagnosesystem
DK1768833T3 (da) Formlegeme, fremgangsmåde til dets fremstilling samt dets anvendelse
GB0509738D0 (en) Processor and interface
WO2008023374A3 (en) Devices and methods for altering eating behavior
ZAA200500119S (en) An animal toy
GB2424658B (en) An acoustic cavity stop
GB0724056D0 (en) Oxygenation of aqueous systems
EP1797186A4 (de) Expressionssystem, dessen komponenten und verwendungsverfahren
WO2007084753A3 (en) Skin cleansing article
EP1769854A4 (de) Ultraschallwandler
AU2003304184A1 (en) Sars coronaviruses 3cl protease 3d-structure model and anti-sars medicines
WO2005105081A3 (en) Therapeutic formulations of desoxyepothilones
EP1742602A4 (de) Hautfreundliche windel
UA92731C2 (ru) Лекарственное средство для гигиеничной обработки уха
EP1811807A4 (de) Ultraschallumwandler
WO2006095173A3 (en) Medical uses of 39-desmethoxyrapamycin and analogues thereof
ZA200705080B (en) Aminocarboxylic acid derivative and medicinal use thereof
EP1623222A4 (de) Ranbp2 als modifikator des pten/igf-wegs und verwendungsverfahren
GB2410027B (en) Animal disease models and uses thereof
GB0409257D0 (en) Disease models and uses thereof
TJ436B (en) The bitter tincture "the bowl of love"
EP1940469A4 (de) Tiermedikament und herstellungsverfahren

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KN KP KR KZ LC LK LR LS LT LU LV LY MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: CR2007-009142

Country of ref document: CR

WWE Wipo information: entry into national phase

Ref document number: 2005816509

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 3947/DELNP/2007

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: MX/a/2007/006689

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 555640

Country of ref document: NZ

Ref document number: 2594103

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 183744

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 200580042359.4

Country of ref document: CN

Ref document number: 2007544787

Country of ref document: JP

Ref document number: 12007501205

Country of ref document: PH

Ref document number: 07058589

Country of ref document: CO

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 1020077014903

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 11721204

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 2005313602

Country of ref document: AU

Ref document number: 2007125570

Country of ref document: RU

ENP Entry into the national phase

Ref document number: 2005313602

Country of ref document: AU

Date of ref document: 20051203

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2005313602

Country of ref document: AU

WWP Wipo information: published in national office

Ref document number: 2005816509

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 183744

Country of ref document: IL

ENP Entry into the national phase

Ref document number: PI0518855

Country of ref document: BR